|
1
|
Román-Fernández A, Mansour MA, Kugeratski FG, Anand J, Sandilands E, Galbraith L, Rakovic K, Freckmann EC, Cumming EM, Park J, Nikolatou K, Lilla S, Shaw R, Strachan D, Mason S, Patel R, McGarry L, Katoch A, Campbell KJ, Nixon C, Miller CJ, Leung HY, Le Quesne J, Norman JC, Zanivan S, Blyth K, Bryant DM. Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function. Sci Adv 2023; 9:eabq1858. [PMID: 36735782 PMCID: PMC9897673 DOI: 10.1126/sciadv.abq1858] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Accepted: 01/03/2023] [Indexed: 06/18/2023]
Abstract
The glycocalyx component and sialomucin podocalyxin (PODXL) is required for normal tissue development by promoting apical membranes to form between cells, triggering lumen formation. Elevated PODXL expression is also associated with metastasis and poor clinical outcome in multiple tumor types. How PODXL presents this duality in effect remains unknown. We identify an unexpected function of PODXL as a decoy receptor for galectin-3 (GAL3), whereby the PODXL-GAL3 interaction releases GAL3 repression of integrin-based invasion. Differential cortical targeting of PODXL, regulated by ubiquitination, is the molecular mechanism controlling alternate fates. Both PODXL high and low surface levels occur in parallel subpopulations within cancer cells. Orthotopic intraprostatic xenograft of PODXL-manipulated cells or those with different surface levels of PODXL define that this axis controls metastasis in vivo. Clinically, interplay between PODXL-GAL3 stratifies prostate cancer patients with poor outcome. Our studies define the molecular mechanisms and context in which PODXL promotes invasion and metastasis.
Collapse
Affiliation(s)
- Alvaro Román-Fernández
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - Mohammed A. Mansour
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- Cancer Biology and Therapy Lab, Division of Human Sciences, School of Applied Sciences, London South Bank University, London SE1 0AA, UK
- Biochemistry Division, Department of Chemistry, Faculty of Science, Tanta University, Tanta 31527, Egypt
| | - Fernanda G. Kugeratski
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
- Department of Immunology, The University of Texas MD Anderson Cancer Center, 7455 Fannin Street, Houston, TX 77054, USA
| | | | - Emma Sandilands
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | | | - Kai Rakovic
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - Eva C. Freckmann
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - Erin M. Cumming
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - Ji Park
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - Konstantina Nikolatou
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | | | - Robin Shaw
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | | | - Susan Mason
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | | | | | - Archana Katoch
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | | | - Colin Nixon
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - Crispin J. Miller
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - Hing Y. Leung
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - John Le Quesne
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - James C. Norman
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - Sara Zanivan
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - Karen Blyth
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| | - David M. Bryant
- Institute of Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK
- The CRUK Beatson Institute, Glasgow G61 1BD, UK
| |
Collapse
|
|
2
|
Rakovic K, Colling R, Browning L, Dolton M, Horton MR, Protheroe A, Lamb AD, Bryant RJ, Scheffer R, Crofts J, Stanislaus E, Verrill C. The Use of Digital Pathology and Artificial Intelligence in Histopathological Diagnostic Assessment of Prostate Cancer: A Survey of Prostate Cancer UK Supporters. Diagnostics (Basel) 2022; 12:1225. [PMID: 35626380 PMCID: PMC9141178 DOI: 10.3390/diagnostics12051225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Revised: 05/09/2022] [Accepted: 05/11/2022] [Indexed: 12/03/2022] Open
Abstract
There has been particular interest in the deployment of digital pathology (DP) and artificial intelligence (AI) in the diagnosis of prostate cancer, but little is known about the views of the public on their use. Prostate Cancer UK supporters were invited to an online survey which included quantitative and qualitative questions exploring views on the use of DP and AI in histopathological assessment. A total of 1276 responses to the survey were analysed (response rate 12.5%). Most respondents were supportive of DP (87%, 1113/1276) and of testing AI in clinical practice as a diagnostic adjunct (83%, 1058/1276). Respondents saw DP as potentially increasing workflow efficiency, facilitating research, education/training and fostering clinical discussions between clinician and patient. Some respondents raised concerns regarding data security, reliability and the need for human oversight. Among those who were unsure about AI, information was requested regarding its performance and others wanted to defer the decision to use it to an expert. Although most are in favour of its use, some are unsure, and their concerns could be addressed with more information or better communication. A small minority (<1%) are not in favour of the testing of the use of AI in histopathology for reasons which are not easily addressed.
Collapse
Affiliation(s)
- Kai Rakovic
- Institute of Cancer Sciences, University of Glasgow, Switchback Road, Glasgow G61 1QH, UK
- Department of Pathology, Queen Elizabeth University Hospital, Govan Road, Glasgow G51 4TF, UK
| | - Richard Colling
- Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (R.C.); (L.B.); (C.V.)
- Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (M.D.); (A.D.L.); (R.J.B.); (R.S.); (J.C.); (E.S.)
| | - Lisa Browning
- Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (R.C.); (L.B.); (C.V.)
- NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK
| | - Monica Dolton
- Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (M.D.); (A.D.L.); (R.J.B.); (R.S.); (J.C.); (E.S.)
| | | | - Andrew Protheroe
- Department of Oncology, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, UK;
- Oxford Cancer & Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Old Road, Oxford OX3 7LE, UK
| | - Alastair D. Lamb
- Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (M.D.); (A.D.L.); (R.J.B.); (R.S.); (J.C.); (E.S.)
- Department of Urology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Old Road, Oxford OX3 7LE, UK
| | - Richard J. Bryant
- Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (M.D.); (A.D.L.); (R.J.B.); (R.S.); (J.C.); (E.S.)
- Department of Urology, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Old Road, Oxford OX3 7LE, UK
| | - Richard Scheffer
- Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (M.D.); (A.D.L.); (R.J.B.); (R.S.); (J.C.); (E.S.)
| | - James Crofts
- Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (M.D.); (A.D.L.); (R.J.B.); (R.S.); (J.C.); (E.S.)
| | - Ewart Stanislaus
- Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (M.D.); (A.D.L.); (R.J.B.); (R.S.); (J.C.); (E.S.)
| | - Clare Verrill
- Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (R.C.); (L.B.); (C.V.)
- Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; (M.D.); (A.D.L.); (R.J.B.); (R.S.); (J.C.); (E.S.)
- NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK
| |
Collapse
|